Tanvex BioPharma Competitors and Similar CompaniesClear all

Tanvex BioPharma's competitors and similar companies include OBI Pharma, PharmaEssentia and Bora Pharmaceuticals.

	Tanvex BioPharma Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs.	OBI Pharma OBI Pharma (台灣浩鼎) is a bio-pharma company focused on cancer therapeutics.	PharmaEssentia PharmaEssentia (藥華醫藥股份有限公司) is a biotech company focused on the areas of hematology, oncology, dermatology, and infectious diseases.	Bora Pharmaceuticals Bora Pharmaceuticals is a company that develops, manufactures, and sells branded, generic, and over the counter (OTC) healthcare products.
Founding Date	Founding Date 2013	Founding Date 2002	Founding Date 2003	Founding Date 2007
Type	Type Public	Type Public	Type Public	Type Private
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development outsourcing pharma
Locations	Locations Taipei, TW HQ New Taipei, TW Irvine, US San Diego, US San Diego, US	Locations TW HQ San Diego, US	Locations Taipei, TW HQ Shinjuku City, JP Burlington, US	Locations TW HQ Wilmington, US
Employees	Employees 13628% decrease	Employees 124	Employees 4897% increase	Employees 6153% increase
Financial
Revenue (est.)	Revenue (est.) NT$61.4m (FY, 2023)	Revenue (est.) NT$41.5m (FY, 2023)	Revenue (est.) NT$9.7b (FY, 2024)	Revenue (est.) N/A
Cost of goods	Cost of goods NT$1.7m (FY, 2023)	Cost of goods NT$115m (FY, 2023)	Cost of goods NT$809.5m (FY, 2024)	Cost of goods N/A
Gross profit	Gross profit NT$61.6m (FY, 2023)	Gross profit (NT$63.8m) (FY, 2023)	Gross profit NT$8.9b (FY, 2024)	Gross profit N/A
Net income	Net income (NT$2.1b) (FY, 2023)	Net income (NT$1.3b) (FY, 2023)	Net income NT$3b (FY, 2024)	Net income N/A